Skip to main content

Aggravated endothelial endocrine dysfunction and intimal thickening of renal artery in high-fat diet-induced obese pigs following renal denervation



Renal denervation (RDN) targeting the sympathetic nerves in the renal arterial adventitia as a treatment of resistant hypertension can cause endothelial injury and vascular wall injury. This study aims to evaluate the risk of atherosclerosis induced by RDN in renal arteries.


A total of 15 minipigs were randomly assigned to 3 groups: (1) control group, (2) sham group, and (3) RDN group (n = 5 per group). All pigs were fed a high-fat diet (HFD) for 6 months after appropriate treatment. The degree of intimal thickening of renal artery and the conversion of endothelin 1 (ET-1) receptors were evaluated by histological staining. Western blot was used to assess the expression of nitric oxide (NO) synthesis signaling pathway, ET-1 and its receptors, NADPH oxidase 2 (NOX2) and 4-hydroxynonenal (4-HNE) proteins, and the activation of NF-kappa B (NF-κB).


The histological staining results suggested that compared to the sham treatment, RDN led to significant intimal thickening and significantly promoted the production of endothelin B receptor (ETBR) in vascular smooth muscle cells (VSMCs). Western blotting analysis indicated that RDN significantly suppressed the expression of AMPK/Akt/eNOS signaling pathway proteins, and decreased the production of NO, and increased the expression of endothelin system proteins including endothelin-1 (ET-1), endothelin converting enzyme 1 (ECE1), endothelin A receptor (ETAR) and ETBR; and upregulated the expression of NOX2 and 4-HNE proteins and enhanced the activation of NF-kappa B (NF-κB) when compared with the sham treatment (all p < 0.05). There were no significant differences between the control and sham groups (all p > 0.05).


RDN aggravated endothelial endocrine dysfunction and intimal thickening, and increased the risk of atherosclerosis in renal arteries of HFD-fed pigs.

Peer Review reports


Resistant hypertension, exhibiting elevated office blood pressure (BP, ≥130/80 mmHg), is a kind of common and complicated disease in clinical practice and is difficult to achieve control in patients despite treated with 3 or more different anti-hypertensive agents at best doses together including a diuretic according to the American Heart Association hypertension guidelines, which leads to increasing incidence of many complications such as renal injury, stroke and heart failure [1,2,3]. Research shows that sympathetic nerve overactivity is relevant to the development of hypertension [4]. Therefore, new therapeutics targeting sympathetic nerves are essential to treatment for resistant hypertension. Renal denervation (RDN) is an invasive technique for resistant hypertension via catheter-based radiofrequency ablation and has been shown to be effective in reducing BP in the Symplicity HTN-1 and Symplicity HTN-2 clinical trials [4, 5]. In addition, some studies have been conducted in clinical and preclinical animal models to assess the safety of the procedure, yet some problems, such as a short observation period, limited research scope including renal function, imaging and morphology of renal artery, exist [4,5,6]. The effects of the RDN procedure on the renal artery still need further study because radiofrequency energy is delivered transmurally and can cause vascular wall injury, which may cause endothelial dysfunction and result in an imbalanced release of an increased level of the endothelium-derived relaxation factor nitric oxide (NO) and a decreased level of the endothelium-derived constriction factor endothelin-1 (ET-1), thereby increasing the risk of atherosclerosis [7]. In addition, studies suggest a number of mechanisms of atherosclerosis, including the thrombosis theory, lipid infiltration theory, damage reaction hypothesis, oxidative stress hypothesis, immune dysfunction hypothesis, homocysteine hypothesis and inflammatory reaction theory [8, 9]. The vascular injury method combined with the use of a high-fat diet (HFD) may accelerate atherosclerosis progression [10, 11].

Based on these considerations, we studied the endothelial endocrine function of and intimal changes to the renal artery and aimed to evaluate the risk of adverse vascular outcomes after RDN in minipigs fed a HFD for 6 months.



All animal experimental protocols mentioned in this study were in accord with the Guidelines for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85–23, revised 1996) and were approved by the Ethics Committee of Zhengzhou University. Fifteen 8-month-old male Bama minipigs weighing 19–20 kg were provided by the Beijing Shi Chuang Century Minipig Breeding Base and were randomly divided into 3 groups: the control group (n = 5), the sham group (n = 5), and the RDN group (n = 5). All pigs were housed individually in pens with a suitable temperature (23 ± 1 °C) and humidity (50 ± 5%) and given access to a HFD (4100 kcal/kg) containing 10% protein, 41% fat, 43% carbohydrates and 6% minerals according to feeding guidelines at 5% of their body weight for 6 months after appropriate treatment and were then euthanized in deep anesthesia using propofol and bensulfatracurium by intravenous injection.

Bilateral RDN procedure

Under anesthesia, the femoral arteries were punctured by the vascular incision method. A 7F sheath (Cordis Corporation, Florida, USA) was introduced into the artery and secured. Each pig was heparinized at 100 U/kg. The angiographic catheter (Cordis Corporation, Florida, USA) was inserted into the abdominal aortic region of the origin of the renal artery. In the RDN group, we performed renal arterial bilateral angiography to ascertain the renal artery location and to assess the feasibility of the RDN procedure. The angiographic catheter was withdrawn followed by insertion of the temperature-controlled cardiac radiofrequency catheter (NS7TCDL174HS, Biosense Webster, California, USA), which was connected to a generator (Johnson & Johnson, New Jersey, USA). Five radiofrequency ablation sites at intervals of 5 mm were selected, and RDN was performed bilaterally in a longitudinal and rotational manner from the distal to the proximal segments of the renal artery. The generator parameters were set as follows: energy, 8 W; and time at each site, 120 s [4]. The sham group underwent the same procedure except for the ablation, while the control group received no treatment.

After 6 months, all pigs were euthanized in deep anesthesia, and the ablated renal arteries from the RDN group and unablated renal arteries from the control and sham groups were obtained and processed for further analysis.

Detection of metabolic profiles

Under anesthesia, the blood was collected from the superior vena cava of pigs using evacuated tubes, and then was centrifuged at 3000 r for 10 min in a desktop high-speed refrigerated centrifuge (Neofuge 15R, Heal Force, Shanghai, China) to separate the serum. Total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and serum creatine (Scr) were measured by automatic biochemical analyzer (Chemray 240, Rayto, Shenzhen, China).

Measurement of BP

To evaluate the effectiveness of RDN, systolic blood pressure (SBP) and diastolic blood pressure (DBP) of all pigs were measured by intelligent non-invasive sphygmomanometer (BP-2010E, Softron, Beijing, China) at baseline and at 2 days, 3 months and 6 months after different treatment. BP was taken 3 times and average figure would be available.

Determination of NO and cGMP levels

After the renal arteries were homogenized, a colorimetric assay kit (No. A012–1, Jiancheng, Nanjing, China) was used according to the manufacturer’s protocol to detect the nitrite content in the supernatant, which was converted from nitrate by nitrite reductase, to reflect NO production. Cyclic guanosine monophosphate (cGMP) content in renal artery extracts was measured using a commercial immunoassay (No. E-EL-0083c, Elabscience, Wuhan, China).


The frozen arteries were thoroughly homogenized, and total protein, cytoplasmic protein and nuclear protein were extracted. Subsequently, a BCA Protein Assay Kit (G2026, Servicebio, Wuhan, China) was used to detect protein concentration. Protein samples were separated by SDS-PAGE (10% gel), transferred to PDVF membranes and blocked with 5% skim milk dissolved in 0.5% TBST for 1 h. Then, the membranes were incubated with the primary antibodies rabbit polyclonal anti-NADPH oxidase 2 (NOX2; 1:1000; bs-3889R, Bioss, Beijing, China), rabbit polyclonal anti-4-hydroxynonenal (4-HNE; 1:1000; ab46545, Abcam, Cambridge, UK), mouse monoclonal anti-endothelin 1 (ET-1; 1:500; abx100923, Abbexa, Cambridge, UK), rabbit polyclonal anti-endothelin A receptor (ETAR; 1:1000; ab117521, Abcam, Cambridge, UK), rabbit polyclonal anti-endothelin B receptor (ETBR; 1:1000; ab117529, Abcam, Cambridge, UK), rabbit polyclonal anti-endothelin converting enzyme 1 (ECE1; 1:1000; bs-1190R, Bioss Beijing, China), rabbit polyclonal anti-adenosine 5′-monophosphate (AMP)-activated protein kinase alpha 1/2 (AMPK; 1:1000; abx008836, Abbexa, Cambridge, UK), rabbit polyclonal anti-phosphorylated AMPK alpha (Thr172) (1:1000; 2531, CST, Boston, USA), rabbit polyclonal anti-endothelial nitric oxide synthase (eNOS; 1:1000; ab5589, Abcam, Cambridge, UK), rabbit polyclonal anti-phosphorylated eNOS (Ser1177) (1:1000; 9571, CST, Boston, USA), rabbit polyclonal anti-protein kinase B (Akt; 1:1000; 9272, CST, Boston, USA), rabbit polyclonal anti-phosphorylated Akt (Ser473) (1:1000; 9271, CST, Boston, USA), mouse monoclonal anti-glyceraldehyde phosphate dehydrogenase (GAPDH; 1:25000; GB13002-m-1, Servicebio, Wuhan, China), mouse monoclonal anti-histone H3 (11,000; GB13102–1, Servicebio, Wuhan, China), rabbit monoclonal anti-phosphorylated-I kappa B alpha (Ser32) (p-IκB alpha;1:1000;2859, CST, Boston, USA) and rabbit polyclonal anti- phosphorylated NF-kappa B p65 (Ser529) (p-NF-κB p65; 1:1000; LS-B652–50, LSBio, Seattle, USA) overnight at 4 °C. After washing 3 times with TBST buffer, the membranes were incubated with horseradish peroxidase (HRP)-labeled goat anti-rabbit IgG (H + L) and HRP-labeled goat anti-mouse IgG (H + L) secondary antibodies for half an hour at room temperature. Immunoblotting was quantified by AlphaEaseFC software (Alpha Innotech, California, USA).

Histopathology and immunohistochemistry

Renal arteries were fixed in 4% paraformaldehyde, washed, dehydrated by soaking in a graded ethanol series (75, 85, 90, 95 and 100%) and cleared in xylene. Vessels were paraffin-embedded and sliced into 5-μm sections at a 200-μm interval from the distal (kidney) to proximal (abdominal aorta) region for hematoxylin and eosin (HE) staining. For immunohistochemistry, sections were blocked in 3% bovine serum albumin (BSA) for 30 min and then incubated overnight at 4 °C with the primary antibody anti-ETAR (1:500; ab117521, Abcam, Cambridge, UK) or anti-ETBR (1:500; ab117529, Abcam, Cambridge, UK). Subsequently, the sections were washed, incubated with HRP-labeled goat anti-rabbit secondary antibody for 50 min at room temperature. The immunoreactions were developed with a diaminobenzidine (DAB) chromogenic kit. The nuclei were counterstained with HE.

Statistical analysis

All data were evaluated with SPSS version 20.00 (International Business Machines Corporation, New York, USA) software. BP was indicated by mean ± standard error and other data were expressed as the mean ± standard deviation. Quantitative indicators were compared using the paired samples t-tests within group. Comparisons between groups were carried out using one-way analysis of variance (ANOVA), followed by the least significant difference (LSD) test to determine the statistical significance of the differences between means. P values less than 0.05 were regarded as statistically significant.


Body weight and serum creatinine levels and lipid profiles at baseline and after 6 months

Compared with the baseline, the significant increases of body weight and TC and significant decrease of HDL-C were observed in pigs of control group (p = 0.000, p = 0.013, and p = 0.006, respectively), sham group (p = 0.000, p = 0.029, and p = 0.001, respectively) and RDN group (p = 0.000, p = 0.029, and p = 0.025, respectively) after a 6-month HFD. There was no statistical difference of body weight, Scr, TC, TG, HDL-C and LDL-C between RND group and sham group after 6 months (p = 0.194, p = 0.418, p = 0.890, p = 0.686, p = 0.728 and p = 0.287, respectively, Table 1).

Table 1 Levels of body weight and Scr and lipid profiles

Changes of BP in pigs with and without RDN

After a HFD for 3 and 6 months, SBP and DBP were significantly elevated in pigs of control group (p = 0.005, p = 0.000, p = 0.002 and p = 0.000, respectively) and sham group (p = 0.000, p = 0.000, p = 0.008 and p = 0.003, respectively) when compared with baseline BP. SBP and DBP significantly decreased post-RDN for 2 days in RDN group (p = 0.002 and p = 0.001, respectively), while no significant difference was found in control group (p = 0.051 and p = 0.553, respectively) and sham group (p = 0.230 and p = 0.553, respectively) which underwent different treatment for 2 days. In comparison with sham group, RDN group had apparently lower SBP (p = 0.010, p = 0.004 and p = 0.006, respectively) and DBP (p = 0.039, p = 0.038, and p = 0.031, respectively) after a HFD for 2 days, 3 months and 6 months (Fig. 1).

Fig. 1
figure 1

Effects of RDN treatment on BP at different time. Changes of (a) SBP and (b) DBP in pigs treated differently after 2 days, 3 months and 6 months. Data are expressed as the mean ± standard error. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. baseline; *p < 0.05, **p < 0.01 vs. sham group; n = 5 per group. Abbreviations: RDN, renal denervation; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure

Pathologic examinations

HE staining showed intimal thickening and irregular arrangement of vascular smooth muscle cells (VSMCs) in all 3 groups after a HFD for 6 months. The degree of intimal thickening in the control group and the sham group was comparable (Fig. 2a and b). In comparison with the sham group, the RDN group had significantly increased intimal thickness (Fig. 2b and c).

Fig. 2
figure 2

Representative images of intima stained by HE in the 3 groups (× 200). a Control group, (b) sham group, (c) RDN group. Black double arrows indicate thickening of the intima. Abbreviations: HE, hematoxylin and eosin; RDN, renal denervation

Protein expression of the NADPH oxidase subunit NOX2 and 4-HNE in ablated and unablated renal arteries

Compared to the sham group, the RDN group had significantly increased protein expression of the NADPH oxidase catalytic subunit NOX2 and of 4-HNE resulting from lipid peroxidation of polyunsaturated fatty acids (p = 0.001 and p = 0.015, respectively), while the sham operation did not affect the levels of NOX2 or 4-HNE compared with the control conditions (p = 0.519 and p = 0.932, respectively, Fig. 3).

Fig. 3
figure 3

Effects of RDN treatment on NOX2 and 4-HNE expression. a NOX2, (b) 4-HNE. Data are expressed as the mean ± standard deviation. *p < 0.05, **p < 0.01 vs. sham group; n = 5 per group. Abbreviations: RDN, renal denervation; NOX2, NADPH oxidase 2; 4-HNE,4-hydroxynonenal; GAPDH, glyceraldehyde phosphate dehydrogenase

AMPK/Akt/eNOS signaling pathway proteins expression in renal arties with and without RDN

As shown in Fig. 4, compared to the sham treatment, RDN significantly suppressed the phosphorylation levels of AMPK, Akt and eNOS (p = 0.046, p = 0.015 and p = 0.018, respectively) and significantly reduced the levels of NO and cGMP (p = 0.004 and p = 0.015, respectively) in obese pigs. However, no significant differences were observed between the control and sham groups (p = 0.427, p = 0.557, p = 0.594, p = 0.191, and p = 0.467, respectively).

Fig. 4
figure 4

Effects of RDN on the signaling pathway of NO production. Representative images of Western blots of AMPK/Akt/eNOS pathway protein expression (a) and the corresponding quantitation (b-d); NO (e) and cGMP levels (f) in pig renal arteries. Data are expressed as the mean ± standard deviation. *p < 0.05, **p < 0.01 vs. sham group; n = 5 per group. Abbreviations: RDN, renal denervation; NO, nitric oxide; cGMP, cyclic guanosine monophosphate; AMPK, adenosine 5′-monophosphate (AMP)-activated protein kinase; eNOS, endothelial nitric oxide synthase; Akt, protein kinase B; GAPDH, glyceraldehyde phosphate dehydrogenase

Expression of endothelin system proteins in renal arties with and without RDN

The expression levels of ECE1, ET-1, ETAR and ETBR were determined (Fig. 5) and were similar between the control and sham groups (p = 0.972, p = 0.191, p = 0.540 and p = 0.648, respectively). Compared to the sham group, the RDN group had significantly increased expression levels of ECE1, ET-1, ETAR and ETBR (p = 0.012, p = 0.004, p = 0.000 and p = 0.007, respectively).

Fig. 5
figure 5

Representative images of Western blots of ECE1, ET-1, ETAR and ETBR protein expression (left panel) and the corresponding quantitation (right panel) in the control, sham and RDN groups. Data are expressed as the mean ± standard deviation. *p < 0.05, **p < 0.01, ***p < 0.001 vs. sham group; n = 5 per group. Abbreviations: RDN, renal denervation; ET-1, endothelin-1; ETAR, endothelin A receptor; ETBR, endothelin B receptor; ECE 1, endothelin converting enzyme 1; GAPDH, glyceraldehyde phosphate dehydrogenase

NF-κB activation of renal arteries with RDN

As presented in Fig. 6, RDN significantly enhanced the cytoplasmic expression of p-IκB and the nuclear expression of p-NF-κB p65 compared with the sham treatment (p = 0.037 and p = 0.039, respectively). However, no significant differences in the activation of cytoplasmic p-IκB and nuclear p-NF-κB p65 were observed between the control and sham groups (p = 0.809 and p = 0.899, respectively).

Fig. 6
figure 6

Effects of RDN on the levels of cytoplasmic p-IκB and nuclear p-NF-κB p65 in renal arteries. Levels of (a) p-IκB and (b) p-NF-κB p65 were determined by Western blot analysis. Data are expressed as the mean ± standard deviation. *p < 0.05 vs. sham group, n = 5 per group. Abbreviations: RDN, renal denervation; GAPDH, glyceraldehyde phosphate dehydrogenase; p-IκB, phosphorylated-I kappa B; p-NF-κB p65, NF-kappa B p65

Effects of RDN on the expression of ETAR and ETBR

Immunohistochemistry was used to compare the expression of ETAR and ETBR among the 3 studied groups (Fig. 7). RDN significantly upregulated the expression levels of ETAR in VSMCs compared to the sham operation. The expression of ETBR, which is mainly expressed in endothelial cells under normal physiological conditions [12], was also significantly increased in VSMCs after RDN treatment. However, the expression levels and staining intensity of ETAR and ETBR in the control and sham groups were consistent. Additionally, the expression and staining intensity of ETAR were significantly higher than those of ETBR in the VSMCs of the control and sham groups, while the expression and staining intensity of these two receptors in VSMCs were similar within the RDN group.

Fig. 7
figure 7

Representative images of the immunohistochemical detection of target protein expression in renal arteries (× 200). ETAR in the control (a), sham (b) and RDN (c) groups; ETBR in the control (d), sham (e) and RDN (f) groups. Abbreviations: RDN, renal denervation; ETAR, endothelin A receptor; ETBR, endothelin B receptor


The major findings of the current study were as follows: (1) RDN aggravated endothelial endocrine dysfunction and intimal thickening of renal arteries; (2) RDN significantly increased the renal arterial level of oxidative stress; and (3) RDN significantly activated the nuclear translocation of NF-κB and increased the risk of atherosclerosis of renal arteries.

The endothelium regulates vascular wall homeostasis by releasing vasodilators such as NO and vasoconstrictors such as ET-1. NO is synthesized through the enzymatic conversion of the amino acid L-arginine by eNOS, which can be phosphorylated by an AMPK-dependent pathway at Ser1177 and the PI3K/Akt signaling pathway [13]. In this study, RDN significantly downregulated the phosphorylation level of Akt at position Ser473 and AMPKα at position Thr172 compared to the sham operation. Thus, RDN significantly suppressed the activation of eNOS, decreased the production and activity of NO and cGMP, and can eventually lead to weakened vasodilation, which is one of the earliest events in the pathogenesis of atherosclerosis [14].

ET-1 is produced by ECE1 and regulates vascular tone via ETAR and ETBR. ETAR is located on VSMCs and contributes to their vasoconstricting properties. ETBR is distributed in endothelial cells, in which it promotes vasodilation by releasing NO, and in smooth muscle cells, where it mediates vasoconstriction. Accumulating evidence suggests that ET-1 expression is upregulated in atherogenesis, which induces endothelial dysfunction, VSMC proliferation and migration and vessel constriction [15]. A previous study indicated that there are higher levels of ETAR and ETBR in VSMCs in the medial region of experimental atherosclerotic lesions than in VSMCs of normal arteries. Mixed ETAR and ETBR receptor antagonism can decrease intimal thickening and reduce atherosclerosis caused by the inflammatory response [16]. Consistent with the above evidence, we found that protein expression of ECE1, ET-1 and its receptors significantly increased in the ablated arteries of the RDN group compared with the arteries of the sham group. Moreover, immunohistochemical results showed a stronger immunostaining intensity of ETAR and an increase in ETBR immunoreactivity in renal arterial VSMCs in the RDN group compared with those in the sham group, which suggested an increasing risk of atherosclerosis after RDN. In normal arterial smooth muscle cells, the expression of ETAR is significantly greater than that of ETBR, but in atherosclerotic vessels, the levels of the two molecules were similar [17], which was demonstrated in our findings. The changes in the relative levels of endothelin receptor subtypes may be due to the switching of ETAR expressed predominantly in contractile phenotype VSMCs to ETBR expressed preferentially in synthetic phenotype VSMCs in the process of atherosclerosis [17].

Endothelial dysfunction is clearly involved with oxidative stress [18]. NADPH oxidase is a superoxide-synthesizing enzyme and is detected by enhanced expression of the NADPH oxidase subunit NOX2 in atherosclerotic arteries [18]. Furthermore, 4-HNE is the one of the most abundant and cytotoxic products of lipid peroxidation of polyunsaturated fatty acids, and is regarded as an important marker of oxidative stress and increased in atherosclerosis [19]. In this study, the western blotting results suggested that NOX2 and 4-HNE expression were obviously upregulated in the RDN group compared with the sham group, which suggested aggravated endothelial dysfunction in HFD-fed pigs treated with RDN. Additionally, NF-κB is an important transcription factor that activates inflammatory responses and contributes to early events in the development of atherosclerosis [20]. NF-κB (a heterodimer with subunits p50 and p65) binds to the inhibitor protein IκB in the cytosol in an inactive state, and NF-κB is activated and translocated freely into the nucleus after IκB phosphorylation and degradation in a pathological state [21]. In the present study, increased NF-κB activation, as indicated by significantly upregulated expression of cytoplasmic p-IκB and nuclear p-NF-κB p65, was observed in pigs following RDN compared to the sham operation. Experimental studies suggested that an ETAR antagonist can block the expression of the kinin B1 receptor associated with oxidative stress and inhibit NF-κB activation [22]. Therefore, upregulated ET-1 levels after RDN may contribute to increased activation of NF-κB and oxidative stress.

Our study suggested that body weight and TC significantly increased in all pigs after a HFD for 6 months. Moreover, HFD also elevated BP in control and sham groups pigs. These were consistent with the reports that HFD-induced obesity can lead to abnormal lipid metabolism disorders and endothelial dysfunction, which can promote the occurrence and the development of hypertension [23, 24]. Renal afferent sympathetic nerve fibers transmit signals to central nervous system which generates and sends sympathetic signals to various targets including heart and kidney, resulting in activating or depressing their sympathetic nervous activity and the changes of BP. Renal efferent sympathetic nerve fibers regulate BP by affecting the activity of renin-angiotensin-aldosterone system (RAAS), renal hemodynamics and renal sodium and water excretion [25, 26]. Overactive renal afferent and efferent sympathetic nervous can activate RAAS, promote sodium and water retention, decrease renal blood flow and eventually elevate BP [25, 26]. Our data indicated that eliminating the overactivated renal afferent and efferent sympathetic nervous in renal arteries by RDN significantly reduced SBP and DBP when compared with sham group. Some studies have shown that radiofrequency ablation energy targeting removing sympathetic nervous applied to the arterial wall induced transmural tissue coagulation and loss of endothelium in an acute phase, and transmural media damage coexisted with the presence of proteoglycan at 6 months after RDN [6, 7, 27]. Vascular endothelial cell injury can cause abnormal proliferation and migration, induce the change from a contractile phenotype to a synthetic phenotype of VSMCs, cause vascular wall thickening, and eventually lead to hypertension and atherosclerosis, which is a lipid-initiated, progressive, inflammatory intimal disease [28]. These findings support the present data indicating that because of the dual stimulation of pathophysiological factors and endothelial mechanical injury, the intima was thicker in HFD-fed pigs treated with RDN than in pigs treated with a sham operation. Intimal thickening is associated with early atherosclerosis [29]. A published case report described a patient with resistant hypertension whose renal arteriography findings were normal before RDN (170/90 mmHg) and whose BP was effectively controlled for 3 months after RDN (140/70 mmHg), but the patient developed 75% renal artery stenosis near the ablation site, hypertension recurrence 6 months after RDN (180/92 mmHg), and a decrease in systolic BP to 150 mmHg 1 month after stent implantation [30]. The degree of rapid progression of renal arterial stenosis induced by RDN is unclear, and intimal thickening relevant to RDN may play an essential role [29]. In the present experimental results, no significant difference was observed between the control and sham groups, which suggested the safety of renal arteriography.


This study provided evidence that RDN can aggravate renal arterial endothelial endocrine dysfunction and intimal thickening, and increase the risk of atherosclerosis in HFD-fed pigs. Thus, in clinical practice, we should monitor endothelial function in the ablated renal arteries and serum lipids after RDN, and provide prophylactic anti-inflammatory, anti-endothelial dysfunction and lipid-lowering treatments if necessary, to prevent complications.


The experimental pig was not a hypertensive pig model, and cannot fully reflect the effects of hypertension on endothelial function, and the changes of endothelial function after RDN. In addition, this study mainly discussed the effects of RDN on the risks of renal arterial atherosclerosis from the perspective of pathology and molecular biology. There was a lack of detection using imaging techniques such as Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) which allow high-resolution imaging and help us more clearly observed vascular changes after RDN and more comprehensively explain the effects of RDN on renal arteries.

Availability of data and materials

The datasets that support the findings of this study are available from the corresponding author on reasonable request.



Total cholesterol




High density lipoprotein cholesterol


Low density lipoprotein cholesterol


Serum creatinine


Systolic blood pressure


Diastolic blood pressure


Renin-angiotensin-aldosterone system


Renal denervation


Nitric oxide;ET-1:endothelin-1


High-fat diet


Cyclic guanosine monophosphate


NADPH oxidase 2


4-hydroxynonenal;ET-1:endothelin 1


Blood pressure


Endothelin a receptor


Endothelin B receptor

ECE 1:

Endothelin converting enzyme 1


Adenosine 5′-monophosphate (AMP)-activated protein kinase


Endothelial nitric oxide synthase


Protein kinase B


Glyceraldehyde phosphate dehydrogenase


Phosphorylated-I kappa B

p-NF-κB p65:

NF-kappa B p65


Hematoxylin and eosin


Bovine serum albumin




Vascular smooth muscle cells


  1. Carey RM, Whelton PK, Committee AAHGW: Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med 2018.

  2. Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutierrez OM, Irvin MR, Lackland DT, Oparil S, McClellan W, Warnock DG, et al. Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study. Am J Kidney Dis. 2014;63(5):781–8.

    Article  Google Scholar 

  3. Carey RM, Whelton PK, Committee AAHGW. Prevention, detection, evaluation, and Management of High Blood Pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018;168(5):351–8.

    Article  Google Scholar 

  4. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81.

    Article  Google Scholar 

  5. Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9.

    Article  Google Scholar 

  6. Sakakura K, Tunev S, Yahagi K, O'Brien AJ, Ladich E, Kolodgie FD, Melder RJ, Joner M, Virmani R. Comparison of histopathologic analysis following renal sympathetic denervation over multiple time points. Circ Cardiovasc Interv. 2015;8(2):e001813.

    Article  Google Scholar 

  7. Su E, Zhao L, Gao C, Zhao W, Wang X, Qi D, Zhu L, Yang X, Zhu B, Liu Y. Acute changes in morphology and renal vascular relaxation function after renal denervation using temperature-controlled radiofrequency catheter. BMC Cardiovasc Disord. 2019;19(1):67.

    Article  Google Scholar 

  8. Chen Z, Xu H. Anti-inflammatory and Immunomodulatory mechanism of Tanshinone IIA for atherosclerosis. Evid Based Complement Alternat Med. 2014;2014:267976.

    PubMed  PubMed Central  Google Scholar 

  9. Calvayrac O, Rodriguez-Calvo R, Marti-Pamies I, Alonso J, Ferran B, Aguilo S, Crespo J, Rodriguez-Sinovas A, Rodriguez C, Martinez-Gonzalez J. NOR-1 modulates the inflammatory response of vascular smooth muscle cells by preventing NFkappaB activation. J Mol Cell Cardiol. 2015;80:34–44.

    CAS  Article  Google Scholar 

  10. Mishra V, Sinha SK, Rajavashisth TB. Role of macrophage colony-stimulating factor in the development of neointimal thickening following arterial injury. Cardiovasc Pathol. 2016;25(4):284–92.

    CAS  Article  Google Scholar 

  11. Helkin A, Desai P, Bailey I, Bruch D, Maier KG, Gahtan V. Rat strain determines statin effect on intimal hyperplasia after carotid balloon injury. J Vasc Surg. 2016;63(2):566–7.

    Article  Google Scholar 

  12. Vignon-Zellweger N, Heiden S, Miyauchi T, Emoto N. Endothelin and endothelin receptors in the renal and cardiovascular systems. Life Sci. 2012;91(13–14):490–500.

    CAS  Article  Google Scholar 

  13. Ahsan A, Han G, Pan J, Liu S, Padhiar AA, Chu P, Sun Z, Zhang Z, Sun B, Wu J, et al. Phosphocreatine protects endothelial cells from oxidized low-density lipoprotein-induced apoptosis by modulating the PI3K/Akt/eNOS pathway. Apoptosis. 2015;20(12):1563–76.

    CAS  Article  Google Scholar 

  14. Sanders M. Molecular and cellular concepts in atherosclerosis. Pharmacol Ther. 1994;61(1–2):109–53.

    CAS  Article  Google Scholar 

  15. Rodriguez-Vita J, Ruiz-Ortega M, Ruperez M, Esteban V, Sanchez-Lopez E, Plaza JJ, Egido J. Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res. 2005;97(2):125–34.

    CAS  Article  Google Scholar 

  16. Reel B, Ozkal S, Islekel H, Ozer E, Oktay G, Sozer GO, Tanriverdi S, Turkseven S, Kerry Z. The role of endothelin receptor antagonism in collar-induced intimal thickening and vascular reactivity changes in rabbits. J Pharm Pharmacol. 2005;57(12):1599–608.

    CAS  Article  Google Scholar 

  17. Iwasa S, Fan J, Shimokama T, Nagata M, Watanabe T. Increased immunoreactivity of endothelin-1 and endothelin B receptor in human atherosclerotic lesions. A possible role in atherogenesis. Atherosclerosis. 1999;146(1):93–100.

    CAS  Article  Google Scholar 

  18. Munzel T, Sinning C, Post F, Warnholtz A, Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med. 2008;40(3):180–96.

    Article  Google Scholar 

  19. Shoeb M, Ansari NH, Srivastava SK, Ramana KV. 4-Hydroxynonenal in the pathogenesis and progression of human diseases. Curr Med Chem. 2014;21(2):230–7.

    CAS  Article  Google Scholar 

  20. Pamukcu B, Lip GY, Devitt A, Griffiths H, Shantsila E. The role of monocytes in atherosclerotic coronary artery disease. Ann Med. 2010;42(6):394–403.

    CAS  Article  Google Scholar 

  21. Hayden MS, Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012;26(3):203–34.

    CAS  Article  Google Scholar 

  22. Morand-Contant M, Anand-Srivastava MB, Couture R. Kinin B1 receptor upregulation by angiotensin II and endothelin-1 in rat vascular smooth muscle cells: receptors and mechanisms. Am J Phys Heart Circ Phys. 2010;299(5):H1625–32.

    CAS  Google Scholar 

  23. Schafer N, Lohmann C, Winnik S, van Tits LJ, Miranda MX, Vergopoulos A, Ruschitzka F, Nussberger J, Berger S, Luscher TF, et al. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur Heart J. 2013;34(45):3515–24.

    Article  Google Scholar 

  24. Moorhouse RC, Webb DJ, Kluth DC, Dhaun N. Endothelin antagonism and its role in the treatment of hypertension. Curr Hypertens Rep. 2013;15(5):489–96.

    CAS  Article  Google Scholar 

  25. Wang TD, Lee YH, Chang SS, Tung YC, Yeh CF, Lin YH, Pan CT, Hsu CY, Huang CY, Wu CK, et al. 2019 consensus statement of the Taiwan hypertension society and the Taiwan Society of Cardiology on renal denervation for the Management of Arterial Hypertension. Acta Cardiol Sin. 2019;35(3):199–230.

    PubMed  PubMed Central  Google Scholar 

  26. Johns EJ, Abdulla MH. Renal nerves in blood pressure regulation. Curr Opin Nephrol Hypertens. 2013;22(5):504–10.

    Article  Google Scholar 

  27. Steigerwald K, Titova A, Malle C, Kennerknecht E, Jilek C, Hausleiter J, Nahrig JM, Laugwitz KL, Joner M. Morphological assessment of renal arteries after radiofrequency catheter-based sympathetic denervation in a porcine model. J Hypertens. 2012;30(11):2230–9.

    CAS  Article  Google Scholar 

  28. Bhatta A, Yao L, Xu Z, Toque HA, Chen J, Atawia RT, Fouda AY, Bagi Z, Lucas R, Caldwell RB, et al. Obesity-induced vascular dysfunction and arterial stiffening requires endothelial cell arginase 1. Cardiovasc Res. 2017;113(13):1664–76.

    Article  Google Scholar 

  29. Nakashima Y, Fujii H, Sumiyoshi S, Wight TN, Sueishi K. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol. 2007;27(5):1159–65.

    CAS  Article  Google Scholar 

  30. Vonend O, Antoch G, Rump LC, Blondin D. Secondary rise in blood pressure after renal denervation. Lancet. 2012;380(9843):778.

    Article  Google Scholar 

Download references


We thank all the researchers who participated in this work.


This work was supported by the Henan Province Medical Science and Technology Research Project Grant 201701019. The funding bodies played an important role in providing primary materials for the study and were not involved in data processing or analysis and writing the manuscript.

Author information

Authors and Affiliations



Study design and operation: ES, LZ, CG, WZ, XW, DQ, LZ, XY, BZ and YL. Data collection: ES. Data analysis: ES. Manuscript writing: ES and LZ. Final approval of the manuscript: ES. All authors had read and approved the final manuscript.

Corresponding author

Correspondence to Chuanyu Gao.

Ethics declarations

Ethics approval and consent to participate

All animal experimental protocols mentioned in this study were in accord with the Guidelines for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85–23, revised 1996) and were approved by the Ethics Committee of Zhengzhou University.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Su, E., Zhao, L., Yang, X. et al. Aggravated endothelial endocrine dysfunction and intimal thickening of renal artery in high-fat diet-induced obese pigs following renal denervation. BMC Cardiovasc Disord 20, 176 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • High-fat diet
  • Endothelial dysfunction
  • Renal denervation
  • Intimal thickening
  • Atherosclerosis
  • Hypertension